NVO May 2024 110.000 call
| Previous close | 19.41 |
| Open | 19.41 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 110.00 |
| Expiry date | 2024-05-17 |
| Day's range | 19.41 - 19.41 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Insider MonkeyHere’s How Novo Holdings’ Catalent (CTLT) Acquisition Affects Laughing Water Capital
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
